

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (withdrawn): A method of synergistically enhancing the chemotherapeutic treatment of cancer expressing adenosine A₃ receptors comprising administering to a mammal in need thereof an effective amount of a high affinity adenosine A₃ receptor antagonists either prior to or during administration of a chemotherapeutic cancer agent.


Claim 2 (withdrawn): The method of claim 1 wherein the chemotherapeutic cancer agent is a taxane family compound.

Claim 3 (withdrawn): The method of claim 1 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

Claim 4 (withdrawn): The method of claim 1 wherein the chemotherapeutic cancer agent is a camptothecin compound.

Claim 5 (withdrawn): The method of claim 1 wherein the chemotherapeutic cancer agent is an antibiotic compound.

Claim 6 (previously presented): A method of synergistically enhancing the chemotherapeutic treatment of cancer expressing adenosine A₃ receptors comprising administering to a mammal in need thereof an effective amount of a high affinity adenosine A₃ receptor antagonists either prior to or during administration of a chemotherapeutic cancer agent wherein the high affinity adenosine A₃ receptor antagonist is a compound of the formula:



wherein:

A is imidazole, pyrazole, or triazole;

R is $-C(X)R^1$, $-C(X)-N(R^1)_2$, $-C(X)OR^1$, $-C(X)SR^1$, $-SO_nR^1$, $-SO_nSR^1$ or $-SO_n-N(R^1)_2$;

R^1 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle wherein each R^1 can be different or the same for any particular compound, or, if linked to a nitrogen atom, then taken together with the nitrogen atom, $N(R^1)_2$ forms an azetidine ring or a 5-6 membered heterocyclic ring containing optionally one or more additional heteroatoms selected from N, O, or S;

R^2 is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;


R^3 is furan, pyrrole, thiophene, benzofuran, benzopyrrole, benzothiophene, optionally substituted with one or more substituents selected from the group consisting of hydroxy, acyl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, substituted amino, aminoacyl, acyloxy, acylamino, alkaryl, aryl, substituted aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocycloxy, aminoacyloxy, thioalkoxy, substituted thioalkoxy, $-SO$ -alkyl, $-SO$ -substituted alkyl, $-SO$ -aryl, $-SO$ -heteroaryl, $-SO_2$ -alkyl, $-SO_2$ -substituted alkyl, $-SO_2$ -aryl, $-SO_2$ -heteroaryl, and trihalomethyl;

X is O, S, or NR^1 ;

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

Claim 7 (previously presented): The method of claim 6 wherein the high affinity adenosine A_3 receptor antagonist is a compound of the formula:



wherein:

A is imidazole, pyrazole, or triazole;

R² is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R³ is furan;

R⁶ is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;

or a pharmaceutically acceptable salt thereof.

Claim 8 (currently amended): The method of claim 6 7 wherein R² is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

Claim 9 (currently amended): The method of claim 6 7 wherein A is a triazolo ring.

Claim 10 (currently amended): The method of claim 6 7 wherein A is a pyrazolo ring.

Claim 11 (currently amended): The method of claim 6 7 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.

Claim 12 (previously presented): The method of claim 6 wherein the cancer has multi-drug resistance that is P-glycoprotein dependent.

Claim 13 (currently amended): The method of claim 44 12 wherein the chemotherapeutic cancer agent is a taxane family compound.


Claim 14 (currently amended): The method of claim 44 12 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

Claim 15 (currently amended): The method of claim 44 12 wherein the chemotherapeutic cancer agent is a camptothecin compound.

Claim 16 (currently amended): The method of claim 44 12 wherein the chemotherapeutic cancer agent is an antibiotic compound.

Claim 17 (cancelled)

Claim 18 (currently amended): The method of claim 44 12 wherein the high affinity adenosine A₃ receptor antagonist is a compound of the formula:



wherein:

A is imidazole, pyrazole, or triazole;

R² is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R³ is furan;

R⁶ is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;

or a pharmaceutically acceptable salt thereof.

Claim 19 (currently amended): The method of claim 44 18 wherein R² is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

Claim 20 (currently amended): The method of claim 44 18 wherein A is a triazolo ring.

Claim 21 (currently amended): The method of claim 44 18 wherein A is a pyrazolo ring.

Claim 22-27 (cancelled)

Claim 28 (previously presented): The method of claim 18 wherein the chemotherapeutic cancer agent is a taxane family compound.

Claim 29 (previously presented): The method of claim 18 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

Claim 30 (previously presented): The method of claim 18 wherein the chemotherapeutic cancer agent is a camptothecin compound.

Claim 31 (previously presented): The method of claim 18 wherein the chemotherapeutic cancer agent is an antibiotic compound.

Claim 32 (new): The method of claim 18 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.